Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation

Carcinogenesis

Volumn 30, Issue 5, 2009, Pages 799-807

  Tammali, Ravinder ^a   Reddy, Aramati B M ^a   Ramana, Kota V ^a   Petrash, Mark J ^b   Srivastava, Satish K ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; AZOXYMETHANE; BETA CATENIN; CHEMOKINE; CYCLIN D1; CYCLOOXYGENASE 2; CYTOKINE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PROTEIN KINASE C BETA; SORBINIL;

ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL GROWTH; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DISEASE MODEL; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IN VITRO STUDY; KNOCKOUT GENE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OXIDATIVE STRESS; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ALDEHYDE REDUCTASE; ANIMALS; AZOXYMETHANE; COLONIC NEOPLASMS; DNA PRIMERS; LIPID PEROXIDATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PRECANCEROUS CONDITIONS; PROTEIN KINASE C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 65549117476     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn246     Document Type: Article

References (46)

1. Majer,M. et al. (2007) Oncologists' current opinion on the treatment of colon carcinoma. Anticancer Agents Med. Chem., 7 492-503.
2. Jemal,A. et al. (2005) Cancer statistics 2005. CA Cancer J. Clin., 55, 10-30.
3. Heavey,P.M. et al. (2004) Colorectal cancer and the relationship between genes and the environment. Nutr. Cancer, 48, 124-141.
4. Yang,K. et al. (2005) Dietary components modify gene expression: implications for carcinogenesis. J. Nutr., 135, 2710-2714.
5. Raju,J. et al. (2005) Low doses of beta-carotene and lutein inhibit AOM-induced rat colonic ACF formation but high doses augment ACF incidence. Int. J. Cancer, 113, 798-802.
6. Singh,S.V. et al. (2004) Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J. Biol. Chem., 279, 25813-25822.
7. Durai,R. et al. (2006) Biology of insulin-like growth factor binding protein-4 and its role in cancer. Int. J. Oncol., 28 1317-1325.
8. MacDonald,T. et al. (1999) T cells orchestrate intestinal mucosal shape and integrity. Immunol. Today, 20, 505-510.
9. Cohen,G. et al. (2006) Epidermal growth factor receptor signaling is upregulated in human colonic aberrant crypt foci. Cancer Res., 66, 5656-5664.
10. Bird,R.P. (1987) Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer Lett., 37, 147-151.
11. Pretlow,T.P. et al. (1991) Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res., 51, 1564-1577.
12. Samowitz,W.S. et al. (2007) APC mutations and other genetic and epigenetic changes in colon cancer. Mol. Cancer Res., 5, 165-170.
13. Takahashi,M. et al. (2004) Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci., 95, 475-480.
14. Jackson,L. et al. (2006) Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treat. Res., 130, 39-65.
15. Itzkowitz,S.H. et al. (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 287 G7-G17.
16. Valko,M. et al. (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact., 160, 1-40.
17. Tammali,R. et al. (2006) Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res., 6, 9705-9713.
18. Romero-Giménez,J. et al. (2008) Germ line hypermethylation of the APC promoter is not a frequent cause of familial adenomatous polyposis in APC/MUTYH mutation negative families. Int. J. Cancer, 122, 1422-1425.
19. Tammali,R. et al. (2007) Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells. Cancer Lett., 252, 299-306.
20. Weaver,S.A. et al. (2001) Regulatory role of phosphatidylinositol 3-kinase on TNF-α-induced cyclooxygenase 2 expression in colonic epithelial cells. Gastroenterology, 120, 1117-1127.
21. Atreya,R. et al. (2005) Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin. Rev. Allergy Immunol., 28, 187-196.
22. Duque,J. et al. (2006) Up-regulation of cyclooxygenase-2 by interleukin- 1beta in colon carcinoma cells. Cell. Signal., 18 1262-1269.
23. Panja,A. et al. (1998) The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. J. Immunol., 161, 3675-3684.
24. Rao,C.V. et al. (2002) Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res., 62, 65-70.
25. Ochiai,M. et al. (2003) Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Am. J. Pathol., 163, 1607-1614.
26. Takahashi,M. et al. (2000) Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis, 21, 1319-1327.
27. Ramana,K.V. et al. (2003) Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-a in human lens epithelial cells. FASEB J., 17, 15-17.
28. Srivastava,S.K. et al. (2005) Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev., 26, 380-392.
29. Ramana,K.V. et al. (2002) Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem., 277 32063-32070.
30. Ramana,K.V. et al. (2006) Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation, 114, 1838-1846.
31. Ramana,K.V. et al. (2006) Mitogenic responses of vascular smooth muscle cells to lipid peroxidation-derived aldehyde 4-hydroxy-trans-2-nonenal (HNE): Role of aldose reductase-catalyzed reduction of the HNE-glutathione conjugates in regulating cell growth. J. Biol. Chem., 281, 17652-17660.
32. Srivastava,S. et al. (2006) Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells. Diabetes, 55, 901-910.
33. Murray,N.R. et al. (1999) Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J. Cell Biol., 145, 699-711.
34. Gökmen-Polar,Y. et al. (2001) Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res., 61, 1375-1381.
35. Saraswat,M. et al. (2006) Overexpression of aldose reductase in human cancer tissues. Med. Sci. Monit., 12, CR525-CR529.
36. Kawanishi,S. et al. (2006) Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem., 387, 365-372.
37. Arber,N. et al. (1996) Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110, 669-674.
38. Nath,N. et al. (2003) Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc. Natl Acad. Sci., 100, 12584-12589.
39. Rao,C.V. et al. (2005) Colonic tumorigenesis in BubR1/-ApcMin/ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc. Natl Acad. Sci. 102, 4365-4370.
40. Sakoguchi-Okada,N. et al. (2007) Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem. Pharmacol., 73, 1318-1329.
41. Swamy,M.V. et al. (2004) Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment. Mol. Cancer Ther., 3, 215-221.
42. Jin,J. et al. (2006) Role of aldo-keto reductases in development of prostate and breast cancer. Front. Biosci., 11, 2767-2773.
43. Kawamura,I. et al. (1999) Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice. Anticancer Res., 19, 4105-4111.
44. Moeckel,G.W. et al. (2003) COX2 activity promotes organic osmolyte accumulation and adaptation of renal medullary interstitial cells to hypertonic stress. J. Biol. Chem., 278, 19352-19357.
45. Ho,E.C. et al. (2006) Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes, 55 1946-1953.
46. Price,S.A. et al. (2004) Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: Interactions with aldose reductase. Diabetes, 53 1851-1856.